Diabetes & Obesity

31st March 2024, A/Prof Chee L Khoo In case you have not noticed, there was some disquiet in the cardiovascular community this week on the potential harm intermittent fasting can cause. The headline presentation says “8-hour time-restricted eating linked to a 91% higher risk of cardiovascular death”. Well, any study regarding “diets” are always going […]

28th March 2024, A/Prof Chee L Khoo We all know that high LDL-C is absolutely and adversely associated with cardiovascular mortality and morbidity. It’s been “proven” again and again in large clinical trials and meta-analyses after meta-analyses. Reducing lipids levels have also been shown to reduce cardiovascular (CV) events in secondary as well as in […]

28th March 2024, A/Prof Chee L Khoo We all know that when type 2 diabetes (T2D) presents at a younger age, they tend to be more aggressive in its progression as well as in the complications it causes. The complications also emerge earlier as well more aggressive. There are more cardiovascular events, more renal events […]

7th March 2024, A/Prof Chee L Khoo There was some kerfuffle recently in the lay press about muscle loss with semaglutide. Great horror? Well, it doesn’t matter how you lose the weight. Any significant body weight loss will incur lean body mass loss (LBM). It’s not unique to GLP1-RA injections. Weight loss from bariatric surgery, […]

11th February 2024, A/Prof Chee L Khoo Significant weight loss of >10% body weight has been associated with remission of type 2 diabetes. It’s not surprising, really, is it? The DiRECT trial which reported in 2018 demonstrated that early in T2D, significant weight loss can lead to remission of T2D (1). Importantly, DiRECT showed that […]

11th February 2024, A/Prof Chee L Khoo Hypertriglyceridaemia (HTG) often accompanies hypercholesterolaemia but that is often ignored as it is considered to be a minor villain. Older clinical trials on lipid lowering agents excluded subjects with HTG and that is partly why the significance of HTG is often ignored. The interplay between HTG and atherosclerotic […]

27th January 2024, A/Prof Chee L Khoo We are all pretty much used to weekly GLP1-RA injections for our patients with type 2 diabetes (T2D). Certainly, a lot less needles compared with the once daily or twice daily GLP1-RA injections and therefore more acceptable to patients (including those without diabetes!). Weekly GLP-1 are efficacious in […]

27th December 2023, A/Prof Chee L Khoo When we think about extreme physical activity (EPA) such as marathon running, apart from the perceived issue of wearing out knee and hip joints (that’s another issue, another day), we think about the cardiovascular risks or benefits that comes with this intense physical activity. We explored the issue […]

27th December 2023, A/Prof Chee L Khoo Not surprisingly, if dysglycaemia is the major contributor to microvascular complications in type 2 diabetes (T2D), the same complications must plaque our patients with type 1 diabetes (T1D. However, we haven’t had many major advances in the management for chronic kidney disease (CKD) and cardiovascular disease (CVD) in […]

14th November 2023, A/Prof Chee L Khoo Obesity is a recognised risk factor for cardiovascular disease (CVD). We are all used to treating cardiovascular risk factors such as hypertension, dyslipidaemia and diabetes in an attempt to reduce CV events. We should also treat the obesity, shouldn’t we? Logically, weight reduction should lead to reduction in […]

30th October 2023, Dr Chee L Khoo When we think about precision medicine, we usually think about some fancy, expensive genetic tests that can help us determine ahead of time who is at risk of some serious diseases. This may allow us to target these patients early and reduce morbidity and mortality. There is connotation […]